Published in

Elsevier, Digestive and Liver Disease, 5(48), p. 552-558, 2016

DOI: 10.1016/j.dld.2015.12.013

Links

Tools

Export citation

Search in Google Scholar

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: an international observational study

Journal article published in 2016 by Philippe Ruszniewski, Juan W. Valle, Catherine Lombard-Bohas, Daniel J. Cuthbertson, Petros Perros ORCID, Luboš Holubec ORCID, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E. Caplin
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse.